Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07549919 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of Food on the Bioavailability of AJ201, and Safety, Tolerability, and Pharmacokinetics of AJ201 in Japanese and White Healthy Male Participants
A Phase 1 study, sponsored by AnnJi Pharmaceutical Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT07549919: Recruiting Phase 1 study, sponsored by AnnJi Pharmaceutical Co..
NCT07549919 is a Phase 1 study that is actively recruiting participants, run by AnnJi Pharmaceutical Co.. The registered enrollment target is 26 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07549919, a Phase 1 study, is actively recruiting participants, sponsored by AnnJi Pharmaceutical Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This is a Phase 1, randomized, single-dose, open-label, two-way crossover study to evaluate the effect of food on AJ201, and to evaluate the safety, tolerability, and pharmacokinetics of AJ201 in Japanese and White healthy male participants.
Primary Outcome
AUC0-24hr: Area under the concentration-time curve from zero to 24 hours under fasting and fed conditions
Interventions
- DRUG AJ201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2026-04-09 |
| Est. Completion | 2026-04-27 |
| Phase | Phase 1 |
What NCT07549919 shows while recruiting
NCT07549919 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 1 intervention - of which AJ201 is the first listed.
NCT07549919 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07549919 about?
NCT07549919 is a clinical study titled "A Study to Evaluate the Effect of Food on the Bioavailability of AJ201, and Safety, Tolerability, and Pharmacokinetics of AJ201 in Japanese and White Healthy Male Participants". This is a Phase 1, randomized, single-dose, open-label, two-way crossover study to evaluate the effect of food on AJ201, and to evaluate the safety, tolerability, and pharmacokinetics of AJ201 in Japanese and White healthy male participants.
What is the current status of trial NCT07549919?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2026-04-09. Estimated completion is 2026-04-27.
What interventions are being tested in trial NCT07549919?
The interventions under investigation include: AJ201 (DRUG).
Who is sponsoring clinical trial NCT07549919?
This trial is sponsored by AnnJi Pharmaceutical Co., which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07549919's enrollment target sits among peer trials
26 1482nd of 2000 higher than 506 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI